| Abstract: | Several new anti-HIV drugs show great promise in future treatments. Nelfinavir, especially effective in combination with AZT and 3TC, is a new protease inhibitor with fewer and milder side effects than other protease inhibitors. GW-1592 is a new nucleoside analogue that appears to be more effective than earlier ones in reducing HIV viral loads with minimal side effects. Other news drugs, GW-141U89, DMP-266, ABT-378, and MKC-442, are entering clinical trials. Scientists are considering converting HIV therapy into a specialty due to the complications, such as resistance, tolerance, and the need for compliance, of using these products. |
